Dow Down0.35% Nasdaq Up0.15%

Progenics Pharmaceuticals, Inc. (PGNX)

5.56 Up 0.05(0.82%) 2:36PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Progenics Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591
United States - Map
Phone: 914-789-2800
Fax: 914-789-2817

Index Membership:N/A
Full Time Employees:69

Business Summary 

Progenics Pharmaceuticals, Inc. develops medicines for oncology. The company offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. It also develops Relistor-oral that is in Phase III testing for the treatment of OIC. In addition, the company’s clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma. Further, it develops MIP-1095, a PSMA-targeted small molecule radiopharmaceutical that is in clinical development stage for the treatment of prostate cancer. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide other than Japan; and collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Progenics Pharmaceuticals, Inc.

Corporate Governance 
Progenics Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Sep 1, 2014 is 2. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 6.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Mark R. Baker J.D., 59
Chief Exec. Officer, Director and Member of Science & Strategy Committee
Dr. Paul J. Maddon M.D., Ph.D., 54
Founder, Vice Chairman and Chairman of Nominating & Corp. Governance Committee
Mr. Angelo William Lovallo Jr., 49
Principal Financial Officer, Principal Accounting Officer, VP of Fin. and Treasurer
Dr. Robert J. Israel M.D., 57
Exec. VP of Medical Affairs
Dr. Nitya G. Ray Ph.D., 61
Sr. VP of Manufacturing
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders